Discoveries and Achievements
The MEF2D-rearranged subtype of acute lymphoblastic leukemia (ALL) is linked to poor outcomes. Now a possible targeted therapy has been identified.
National Institutes of Health funding will help physicians and researchers improve hydroxyurea treatment management for sickle cell patients in Memphis.
Research from the Pediatric Cancer Genome Project identifies the mechanism of action for two transcription factors underlying a type of B-precursor acute lymphoblastic leukemia.
Research from the Pediatric Cancer Genome Project identifies genomic landscape that contributes to the diversity of core-binding factor acute myeloid leukemia.
Higher blood levels of methotrexate during treatment of childhood leukemia have been linked to diminished executive function in long-term survivors.
To improve patient safety, hospital leaders should provide feedback that demonstrates to staff the value of reporting safety events and errors.
From Promise, Winter 2017
Donate Now Subscribe to Promise
Thank you for your feedback!
St. Jude Quality of Life for All team goes above and beyond to improve patients’ psychosocial, emotional, and symptom concerns.
St. Jude staff members help children learn, or re-learn, the art of handwriting.
The STARR program provides academic assistance for children with sickle cell disease and hemophilia.
St. Jude Child Life unites five patients and inspires them to help one another persevere.
Teenagers unite to party with a purpose.
A gift of property supports the hospital’s Genomes for Kids clinical trial.
St. Jude scientists use gene editing in quest to help children with sickle cell disease.
There’s ‘clean,’ and then there’s ‘
St. Jude clean.’ Learn some of the tactics
St. Jude uses to keep infection rates low.
Lifestyle expert Sabrina Soto explains how a focus on family makes
St. Jude extra special.
A long-term leukemia survivor runs to help the hospital that saved his life.